ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
High prevalence of sarcopenia, osteoporosis and osteosarcopenia in patients with chronic kidney disease compared with healthy controls.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chronic kidney disease and sarcopenia.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brief rationale: The impact of non-dialysis chronic kidney disease (CKD) on combined muscle and bone decline remains insufficiently described. MAIN
resultPatients with CKD showed markedly higher rates of sarcopenia, osteoporosis, and osteosarcopenia than matched healthy controls. Significance of the paper: These findings support systematic evaluation of muscle and bone health in CKD management. PURPOSE: Chronic kidney disease (CKD) negatively affects bone and muscle quality. The combination of sarcopenia and osteoporosis, osteosarcopenia, is associated with an increased risk of fractures and mortality. Yet, little is known about osteosarcopenia in patients with non-dialysis-dependent CKD compared to healthy controls. We hypothesized that patients with CKD have a higher prevalence of osteosarcopenia than healthy adults.
methodsIn this cross-sectional study, 138 patients with CKD stages G4-5 were matched 1:1 on sex and age to healthy controls. We assessed appendicular lean mass and bone mineral density (BMD) at the hips and lumbar spine using dual-energy X-ray absorptiometry and evaluated muscle strength through handgrip strength, 30-s chair stands, and 10-m gait speed. Sarcopenia was defined using the criteria by the EWGSOP criteria, osteoporosis by the WHO criteria, and osteosarcopenia required the presence of both.
resultsCKD participants had weaker handgrip strength, poorer chair-stand performance, and slower gait speed compared to healthy controls. BMD was reduced in patients with CKD. The prevalence of sarcopenia (21.7% vs. 5.8%; OR 4.51 [1.91-11.8]), osteoporosis (21.7% vs. 10.1%; OR 2.44 [1.25-4.99]), and osteosarcopenia (8.7% vs 1.4%; OR 6.44 [1.39-60.4]) were higher in patients with CKD compared to controls.
conclusionIn this cross-sectional study, there was a higher prevalence of sarcopenia, osteoporosis, and osteosarcopenia in patients with CKD as compared to sex- and age-matched healthy controls. These findings indicate that it is relevant with a systematic assessment of muscle and bone health in CKD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.